Harrow Inc HROW

US Pharmaceuticals

$38.77 ▼ -0.44% ($-0.17)

⬇️ Below Yest. Low 🔥 High Short Interest 🗓️ Earnings Next Week

Open $38.86

Prev Close $38.94

Day Range $37.18 – $39.01

52W Range $28.54 – $54.85

Market Cap $1.45B

Beta 0.24

EPS (TTM) $-0.41

📋 Company Profile

Industry	Pharmaceuticals
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2013-02-08
Shares Out.	37,280,000
Website	harrow.com/ ↗
Phone	16157334731
Employees	373
Revenue	$44.2M
Gross Profit	$27.0M
Net Income	-$27.6M
Free Cash Flow	-$3.7M
Total Assets	$419.5M
Total Liabilities	$391.2M
Equity	$28.4M

About Harrow Inc

Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.

Harrow Inc is a publicly traded company under the ticker symbol HROW on the NASDAQ NMS - GLOBAL MARKET, operating in the Pharmaceuticals industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.